Quantbot Technologies LP Crispr Therapeutics Ag Transaction History

Quantbot Technologies LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$60.67 - $89.12 $79,053 - $116,123	1,303 New	1,303 $88,000
Q3 2023 Nov 07, 2023	BUY	$45.39 - $59.0 $590 - $767	13 New	13 $0
Q2 2022 Aug 09, 2022	BUY	$43.23 - $73.83 $2,896 - $4,946	67 New	67 $4,000
Q3 2021 Nov 09, 2021	SELL	$110.2 - $156.64 $388,014 - $551,529	-3,521 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$100.84 - $161.89 $355,057 - $570,014	3,521 New	3,521 $570,000
Q1 2021 May 14, 2021	SELL	$110.72 - $210.04 $18,490 - $35,076	-167 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $13,304 - $28,929	167 New	167 $25,000
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $56,598 - $72,561	-721 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$38.5 - $76.05 $19,981 - $39,469	519 Added 256.93%	721 $52,000
Q1 2020 May 13, 2020	SELL	$33.68 - $62.53 $90,868 - $168,705	-2,698 Reduced 93.03%	202 $8,000
Q4 2019 Feb 10, 2020	BUY	$36.68 - $73.13 $106,372 - $212,077	2,900 New	2,900 $176,000
Q2 2018 Aug 13, 2018	SELL	$42.62 - $73.59 $60,392 - $104,277	-1,417 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$23.52 - $58.17 $33,327 - $82,426	1,417 New	1,417 $64,000

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.